Autor según el artículo: Rosa-M Valls; Elisabet Llauradó; Sara Fernández-Castillejo; Rosa Solà; Francesc Puiggrós; Lluis Arola; Anna Pedret

Departamento: Bioquímica i Biotecnologia Medicina i Cirurgia

Autor/es de la URV: VALLS ZAMORA, ROSA MARIA; LLAURADÓ RIBÉ, ELISABET; FERNÁNDEZ CASTILLEJO, SARA; SOLÀ ALBERICH, ROSA MARIA; PUIGGROS LLAVINÉS, FRANCESC; AROLA FERRER, LUIS MARIA; PEDRET FIGUEROLA, ANNA

Palabras clave: Cardiovascular biomarkers Systolic blood pressur HDL-c Low weight Molecular procyanidin

Resumen: Background Oligopinۚ (OP) is a quantified extract from French Maritime Pine bark (FMPB) with low molecular weight procyanidins. The cardioprotective effects of OP need to be tested in human clinical intervention trials with an appropriate design. Purpose The aim of the present study was to assess the effect of subchronic consumption of OP on cardiovascular disease risk factors such as lipid profile, systolic blood pressure (BP) and oxidized-Low Density Lipoprotein (ox-LDL) in stage-1-hypertensive subjects. Methods Between February 14 and May 31, 2014, eligible subjects were recruited from the outpatient clinics of Hospital Universitari Sant Joan (Reus, Spain). A total of 24 participants (mean age ± DS; 57.36 ± 11.25; 17 men) with stage-1-hypertension who were not receiving BP-lowering medication and LDL cholesterol < 4.88 mmol/l were randomized in a double-blind, placebo-controlled, crossover study. The subjects received 2 capsules/day with 75 mg of OP or placebo for 5-weeks. Results At 5-weeks, compared to the placebo, OP raised High Density Lipoprotein-cholesterol (HDL-c) by 14.06% (p = 0.012) and apolipoprotein A-1 by 8.12% (p = 0.038) and reduced the ratio of apolipoprotein B-100/A-1 by 10.26% (p = 0.046). Moreover, at 5-weeks, compared to the baseline, OP reduced the systolic BP by 6.36 mmHg (p = 0.014), and decreased ox-LDL concentrations by 31.72 U/l (p = 0.015). Conclusion At 5-weeks, the consumption of 150 mg/day of OP improve lipid cardiovascular profile and represents one of the scarce ways to increase HDL-c in stage-1-hypertensive subjects.

Grupo de investigación: Unitat de Recerca de Lípids i Arteriosclerosi Grup de Recerca en Nutrigenòmica

Áreas temáticas: Health sciences Ciencias de la salud Ciències de la salut

Acceso a la licencia de uso: https://creativecommons.org/licenses/by/3.0/es/

Direcció de correo del autor: rosamaria.valls@urv.cat

ISSN: 0944-7113

Fecha de alta del registro: 2016-09-22

Página final: 1461

Volumen de revista: 23

Versión del articulo depositado: info:eu-repo/semantics/acceptedVersion

Enlace a la fuente original: https://www.sciencedirect.com/science/article/abs/pii/S0944711316301490

DOI del artículo: 10.1016/j.phymed.2016.08.007

Entidad: Universitat Rovira i Virgili

Año de publicación de la revista: 2016

Página inicial: 1451

Tipo de publicación: Article Artículo Article